Use of the Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular) is associated with an increased risk of definite or probable scaffold thrombosis at 1 year and beyond, as well as increased ...

In patients with very long coronary lesions, use of Absorb BVS (Abbott Vascular) is associated with a high rate of TLF at 1 year, driven by MI and clinically driven TLR, according to a subanalysis ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The Absorb bioresorbable scaffold demonstrated overall clinical outcomes comparable to those of the ...

In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the ...